Events & Presentations
Upcoming Events
Date | Event Details | Remind Me |
---|---|---|
Feb 4, 2021 4:30 PM EST
|
Arrowhead Pharmaceuticals 2021 First Quarter Results
|
Archived Events
Date | Event Details |
---|---|
Mar 12, 2019 4:20 PM EDT
|
Barclays Global Healthcare Conference 2019
Miami
Bruce Given, M.D., Arrowhead’s chief operating officer, will deliver a corporate presentation.
|
Feb 22, 2019
|
APASL 2019
View Presentation 770.9 KB
Dr. Edward Gane will deliver a poster presentation titled, “RNA interference (RNAi) in chronic hepatitis B (CHB): Data from Phase 2 study with JNJ-3989”
|
Feb 7, 2019 4:30 PM EST
|
Arrowhead Pharmaceuticals 2019 First Quarter Results
Prepared Remarks 165.2 KB
|
Dec 11, 2018 4:30 PM EST
|
Arrowhead 2018 Fiscal Year End Results
|
Nov 28, 2018
|
30th Annual Piper Jaffray Healthcare Conference
New York, NY
November 28, 3:30 p.m. EST – Dr. Anzalone will participate in a fireside chat
|
Nov 16, 2018
|
China Nucleic Acids
View Presentation 9.3 MB
Guangzhou, China
November 16, 11:20 – Dr. Li will deliver an oral presentation titled, “TRiMTM Platform Based RNAi Therapeutics for AATD and Cardiometabolic Diseases”
|
Nov 15, 2018
|
Jefferies 2018 London Healthcare
View Presentation 10.5 MB
London
November 15, 2:00 p.m. GMT – Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will deliver a corporate presentation
|
Nov 13, 2018
|
30th EORTC-NCI-AACR Symposium
View Presentation 1.4 MB
Dublin
November 13, 10:00 a.m. GMT – Dr. Given will deliver a poster presentation titled, “Targeting HIF2α with an RNAi therapeutic for the treatment of clear cell renal cell carcinoma”
|
Nov 12, 2018
|
American Heart Association Scientific Sessions 2018
AHA 2018 ARO-APOC3 Final 1.4 MB
AHA 2018 ARO-ANG3 Final 5.2 MB
Chicago
November 12, 10:45 a.m. CST – Rui Zhu, Ph.D., Arrowhead’s senior chemist, will deliver an oral presentation titled, “RNA Interference Mediated Apolipoprotein C3 Gene Silencing as a Therapeutic for Hypertriglyceridemia”
November 12, 11:45 a.m. CST – So Wong, Ph.D., Arrowhead’s director of oncology, will deliver an oral presentation titled, “Development of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia” |
Nov 12, 2018
|
The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
AASLD 2018 ARO-HBV Poster 654.3 KB
First Results with RNA interference (RNAi) in Chronic Hepatitis B (CHB) Using ARO-HBV
|